Iradimed (IRMD) Competitors

Iradimed (NASDAQ:IRMD) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Do insiders and institutionals hold more shares of IRMD or PLSE?

92.3% of Iradimed shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 42.6% of Iradimed shares are owned by company insiders. Comparatively, 71.5% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has more risk and volatility, IRMD or PLSE?

Iradimed has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500.

Does the MarketBeat Community prefer IRMD or PLSE?

Iradimed received 4 more outperform votes than Pulse Biosciences when rated by MarketBeat users. However, 65.17% of users gave Pulse Biosciences an outperform vote while only 64.69% of users gave Iradimed an outperform vote.

Company	Underperform	Outperform
Iradimed	Outperform Votes 251 64.69%	Underperform Votes 137 35.31%
Pulse Biosciences	Outperform Votes 247 65.17%	Underperform Votes 132 34.83%

Do analysts prefer IRMD or PLSE?

Iradimed currently has a consensus price target of $62.50, indicating a potential upside of 46.75%. Given Iradimed's higher probable upside, research analysts clearly believe Iradimed is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iradimed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Pulse Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Is IRMD or PLSE more profitable?

Iradimed has a net margin of 26.48% compared to Pulse Biosciences' net margin of 0.00%. Iradimed's return on equity of 24.63% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iradimed	26.48%	24.63%	20.54%
Pulse Biosciences	N/A	-86.15%	-66.87%

Does the media prefer IRMD or PLSE?

In the previous week, Pulse Biosciences had 7 more articles in the media than Iradimed. MarketBeat recorded 10 mentions for Pulse Biosciences and 3 mentions for Iradimed. Iradimed's average media sentiment score of 1.77 beat Pulse Biosciences' score of 1.19 indicating that Iradimed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iradimed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Pulse Biosciences	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings and valuation, IRMD or PLSE?

Iradimed has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iradimed	$65.56M	8.26	$17.19M	$1.41	30.35
Pulse Biosciences	$700K	940.32	-$42.21M	-$0.81	-14.72

Summary

Iradimed beats Pulse Biosciences on 12 of the 17 factors compared between the two stocks.